Ida Genta
Ida Genta
affiliation: University of Pavia
research area(s): Stem Cells And Regenerative Medicine
Course: Biomolecular Sciences and Biotechnology
University/Istitution: Istituto Universitario di Studi Superiori, Pavia
Current position: associate professor of Applied Pharmaceutical Chemistry, University of Pavia, Italy


Dr. Ida Genta was born in Stradella (Pavia), Italy, on 28th January 1961.

1985 - Graduated in Pharmaceutical Chemistry and Technology at the University of Pavia, Pavia, Italy.

1985/1988 - Post Graduate School in Industrial Pharmacy at the University of Pavia, Pavia, Italy.

1988/1991 - PhD in Pharmaceutical Chemistry and Technology at the University of Pavia, Pavia, Italy.

1992/1994 - Post-doctoral Scholarship at the University of Pavia, Pavia, Italy.

1995/2000 - Assistant Professor at the Faculty of Pharmacy, Department of Pharmaceutical Chemistry, University of Pavia, Pavia, Italy.
2001/now - Associate professor at the Faculty of Pharmacy, Department of Pharmaceutical Chemistry, University of Pavia, Pavia, Italy.

Teaching and organizing activity

 Course: Pharmaceutical biotechnology (Pharmaceutical Chemistry and Technology and Pharmacy laurea degree courses) and Technological Test Procedure of Dosage Forms (Pharmacy) at the University of Pavia (Pavia, Italy); Biotech Drug Formulations (Biotechnology laurea degree course).
 Since 1998 tutor of several theses (Pharmaceutical Chemistry and Technology, Pharmacy and Biotechnology).
 Member, Board of International PhD program in Biomolecular Sciences and Biotecnologies (Institute for Advanced Study – IUSS – University of Pavia) and Board of PhD program in Pharmaceutical Chemistry and Technology (University of Pavia and Parma).
 Lectures and tutor of theses in Pharmaceutical Technologies and Regulatory Affairs Master (University of Pavia, Parma, Perugia, Sassari).
 Scientific organizer and speaker in refresher courses ECM (Health Ministery) for pharmacists. Courses: Dispensing Pharmacy, Pharmaceutical Technolgy and Regulatory Affairs, Biotechnology.
 Member of the working group (co-ordinator: prof. Luisa Montanary, University of Milan, Italy) for Istituto Superiore di Sanità (ISS) on: “Chemical-physical properties of drug products and their safety – Sterilization processes and their influence on drug properties” and “ Drug product safety for medical care of elderly – Innovative drug delivery systems for optimized elderly medical care of cardiovascular and antinfiammatory/analgesic treatments”
 Member of Association of researcher and teachers of Pharmaceutical echnology and Legislation (ADRITELF), Italian Controlled Release Society (CRS), Association of Industrial Pharmacists (AFI), American Association of Pharmaceutical Scientists. (AAPS)
 Reviewer for: Journal of Microencapsulation, International Journal of Nanomedicine, Drug Delivery & Industrial Pharmacy, Il Farmaco, Journal of Controlled Release, S.T.P. Pharma Sciences, BMC Immunology, Drug Delivery, International Journal of Pharmaceutics.
Professor Genta's research interests focus on the areas of Pharmaceutical Technology and Applied Pharmaceutical Chemistry.
In the field of Pharmaceutical Technology the research involves:
 investigation on particulate matter contamination of large and small volume parenterals;
 formulation, characterization and study of micro- and nanoparticulate drug delivery systems especially for the delivery of protein drugs of biotech origin: micro- and nanoparticles intended for parenteral, intra-articular and local drug administration and based on biodegradable polymers, sinthetic (poly-lactide, poly-glycolide and copolymers and derivatives) and natural (albumin, hyaluronidase, alginate and chitosan);
 study of the effect of gamma and beta radiations on micro- and nanoparticulate delivery systems made of poly-D,L-lactide-co-glycolide and encapsulating proteins;
 formulation, characterization and study of liposomal systems intended for pharmaceutical and cosmetic applications;
 site-directed PEGylation of proteins and their encapsulation into nano drug delivery systems based on chitosan and its derivatives; ex vivo evaluation of cellular toxicity and of pharmacokinetic profile of protein activity;
 development of polymeric scaffold for tissue regeneration. Researches involve the evaluation of new biodegradable polymers to prepare scaffold matrix, biocompatibility studies of the new materials and of scaffolds, development of new preparation methods for 3D and 2D scaffolds;
 development of new nanoparticulate adjuvant for vaccine delivery.
- R. Dorati, C. Colonna, I. Genta, T. Modena, B. Conti, Effect of porogen on the physicochemical properties and degradation performance of PLGA scaffolds.
Polymer Degradation and Stability (2009) e-first, 1-8. - R. Dorati, I. Genta, C. Tomasi, , T. Modena, C. Colonna , F. Pavanetto, P.Perugini, B. Conti, Polyethylenglycol-co-poly-D,L-lactide copolymer based microspheres: Preparation, characterization and delivery of a model protein. Journal of Microencapsulation (2008) 25 (5), 330-338. - C. Colonna, B. Conti, P.Perugini, F. Pavanetto, T. Modena, R. Dorati, P. Iadarola, I. Genta,Site-directed PEGylation as success full approach to improve the enzyme replacement in the case of prolidase. International Journal of Pharmaceutics (2008) 358, 230-237.- R. Dorati, C. Colonna, M. Serra, I. Genta, T. Modena, F. Pavanetto, P. Perugini, B. Conti,Gamma-irradiation of PEGd,lPLA and PEG-PLGA multi block copolymers: I. Effect of irradiation doses. AAPS Pharm. Sci. Tech. (2008) 9, 718-25.- C. Colonna, B. Conti, P.Perugini, F. Pavanetto, T. Modena, R. Dorati, P. Iadarola, I. Genta, Ex vivo evaluation of prolidase loaded chitosan nanoparticles for enzyme replacement therapy” European Journal of Pharmaceutics and Biopharmaceutics (2008) 70, 58-65. - C. Colonna, B. Conti, I. Genta, O. Alpar, Non-viral dried powders for respiratory gene delivery prepared by cationic and chitosan loaded liposomes.International Journal of Pharmaceutics (2008) 364, 108-118.- R. Dorati, I. Genta, T. Modena, F. Pavanetto, P. Perugini, B. Conti, C. Colonna,Investigation of the degradation behaviour of poly(ethylene glycol-co-D,L-lactide) copolymer. Polymer Degradation and Stability (2007) 92, 1660-1668. - C. Colonna, B. Conti, P.Perugini, F. Pavanetto, T. Modena, R. Dorati, I. Genta, Chitosan glutamate nanoparticles for protein delivery: development and effect on prolidase stability. Journal of Microencapsulation (2007) 24, 553-564.- C. Colonna, I. Genta, P. Perugini, F. Pavanetto, T. Modena, M. Valli, C. Muzzarelli, B. Conti. 5-Methyl-Pyrrolidinone chitosan films as carriers for buccal administration of proteins.AAPS PharmSciTech (2006) 7, 1-7.- K. Maculotti, I. Genta, P. Perugini, M. Imam, A. Bernkop-Schnurch, F. Pavanetto, Preparation and in vitro evaluation of thiolated chitosan microparticles.Journal of Microencapsulation 22(5), 459-470, 2005. - I. Genta et al. Evaluation of bioadhesive performance of chitosan derivatives as films for buccal application. Journal of Drug Delivery Science and Technology, 16(6), 459-463, 2005. - I. Genta,et al. Miconazole-loaded 6 oxychitin-chitosan microcapsules. Carbohydrate Polymers, 52, 11-18, 2003.-Patent,Inventors: P. Perugini, K. Hassan, C. Colonna, I. Genta, T. Modena, F. Pavanetto, P. Iadarola, B. Conti Owner: Università degli Studi di Pavia Title: "Interactive medication for dermatologic deseases (Medicazioni interattive per la cura di patologie dermatologiche)" Patent n.: MI2006A000556 (24/03/2006.European Extension in progress

Project Title:
This research project is aimed to design, develop, characterize and in vivo assess different nanostructured materials as innovative particulate adjuvants for protein vaccines. Thanks to their safety, such type of antigens should represent a useful tool for preventing a lot of serious pathologies, ranging from infectious
diseases (hepatitis, HIV etc.) to other pathologies such as cancer, neurodegenerative and autoimmune diseases. Known the poor immunogenicity of the recombinant protein antigens, the implementation of efficient vaccines requires potent and safe adjuvants, namely nanostructured particulate adjuvants able
to protect the antigens, prolong and control their release as well as to elicit humoral, cellular and mucosal immunity. Considering the market, only very few vaccine adjuvants have been approved for use in humans. Alumina, considered a benchmark in this field, are the unique adjuvant used in licensed human
vaccine in Europe and United States; furthermore, the only nanosized vaccine adjuvant approved for human use thus far, MF59 (an oil-in-water emulsion composed of squalene and two surfactants), is not yet licensed in the United States.
Because of the need of specific and more potent adjuvants for an efficient vaccination with protein antigens, the project should be considered of particular interest in order to fulfil this gap; moreover, this project results smartly oriented to the develop of advanced adjuvants technologies to be simply
implemented at industrial level.
The project will consider different approaches in order to achieve the final goal. In particular, polymeric and lipid-based nanostructured particles will be thoroughly designed in order to get the crucial characteristics of the high antigen loading and control release on one side, and of the targeted antigen
delivery to antigen-presenting cells on the other side, in order to finally improve vaccine efficacy and safety. There are several reasons to support the development of innovative materials as adjuvants to get efficient
recombinant protein vaccines. First, vaccines are one of the most effective ways to protect people against infectious diseases and thereby actively promote better health and quality of life, locally as well as globally. Second, vaccines are one of the most cost-effective measures for public health with respect to
repeated applications of drugs or other therapeutic treatments. Third, the possibility of creating vaccines for a host of non-infectious disease such as cancer, neurodegenerative disease and autoimmune disease.

Project Title:
Nanostructured polymeric 3-D scaffolds for bone regeneration.
The research project is addressed to the production and in vitro, ex vivo evaluation of 3D- polymeric scaffolds for bone regeneration therapies made of new
biodegradable polymers selected to improve the mechanical properties and to control degradation properties of scaffold
The objectives to be achieved are:

 Selection of one funtionalized polylactide polymer which is suitable to prepare scaffold for bone tissue repair;

 Set up of scaffolds procedure for the preparation of scaffold useful for the cells growth and proliferation. The study will consider the polymeric materials that will be used and those parameters related to product safety and efficacy, and industrial parameters such as yield of production.

 To achieve high porosity tridimensional scaffolds with compressive resistance higher than autologous and allogenic bone implants and with the biological performances in terms of cell viability, proliferation and bone matrix deposition;

 Assessment of the in vitro degradation performances during the incubation into simulated physiological conditions;

 Assessment of the gamma irradiation treatment on the scaffold properties and performance;

 Assessment of the biological performances of the scaffolds in terms of cell viability, proliferation and bone matrix deposition;

 Possible scale-up of the scaffold preparation method starting from the selected polymers.

The final goal is to obtain tissue-engineered constructs suitable to be implanted in the human body.